1. Affiliated Hospital,Inner Mongolia Medical University,Hohhot 010050,China; 2. School of Pharmacy,Inner Mongolia Medical University,Hohhot 010110,China
Abstract��OBJECTIVE To prepare a nasal gel of risperidone (RIS) and evaluate its in vitro quality. METHODS The formulation and preparation process of RIS nasal gel were optimized with orthogonal test using appearance,spreading ability and in vitro release as main evaluation indexes. The quality items of the optimized RIS nasal gel such as appearance,pH value,contents of RIS and preservative,in vitro release and related substances were then evaluated. RESULTS The optimal formulation of the RIS nasal gel consisted of 0.5% RIS,0.35% carbopol 940,0.5% chlorobutanol,20% propanediol and 15% DM-��-CD and appropriate amount of purified water. Its ideal pH value was about 6.0. Furthermore,the quality items such as the appearance,pH value,contents of RIS and preservative,in vitro release and related substances of the preparation all conformed to the relevant quality requirements in China Pharmacopiea (2010). CONCLUSION The RIS nasal gel will be a promising new preparation for nasal administration due to its reasonable formulation,simple preparation process and controllable quality.
TAKEUCHI H,FERVAHA G,LEE J,et al. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia [J]. Eur Neuropsychopharmacol,2015,25(3):295-302.
[2]
SUBOTNIK K L,CASAUS L R,VENTURA J,et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia :A randomized clinical trial[J]. JAMA Psychiatry,2015,72(8):822-829.
[3]
CABALEIRO T,OCHOA D,L��PEZ-RODR�MGUEZ R, et al. Effect of polymorphisms on the pharmacokinetics,pharmacodynamics,and safety of risperidone in healthy volunteers[J]. Hum Psychopharmacol,2014,29(5):459-469.
[4]
ZUO Z H,TANG S F,WANG W. Determination of dissolution of risperidone capsules[J]. Tanjin Pharm (���ҩѧ),2013,25(3):8-9.
[5]
MOHAMMED K A,IBRAHIM H K,GHORAB M M. Effervscent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone[J]. Drug Deliv,2014,15(1):1-10.
[6]
COSTANTION H R,ILLUM L,BRANDT G, et al. Intranasal delivery:Physicochemical and therapeutic aspects[J]. Int J Pharm,2007,337(1) :1-24.
[7]
HASCHKE M,SUTER K,HOFMANN S,et al. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam[J]. Br J Clin Pharmacol,2010,69(2):607-616.
[8]
SERRALHEIRO A,ALVES G,FORTUNA A,et al. Intranasal administration of carbamazepine to mice:A direct delivery pathway for brain targeting[J]. Eur J Pharm Sci,2014,60(1):32-39.
[9]
MA W N,GU F G. Effect of pH on the chemical stability,solubility and oil-water partition coefficient of risperidone [J]. Cent South Pharm (����ҩѧ),2015,13(5):473-476.
[10]
FAN Y F,LI D M,XU X J. The prescription and quality assessment of the compound ketoconazone gel[J]. Pharm Clin Res (ҩѧ���ٴ��о�),2007,15(4):323-325.
[11]
ZHAO Q,YANG Y W,DENG S H,et al. Study on the formulation of atenolol nasal gel[J]. Chin Hosp Pharm J (�й�ҽԺҩѧ��־),2005,25(1):27-29.
[12]
LIU H W,YAN Y L,ZHOU L L. Prescription optimization of ligustrazine phosphate pH-sensitive in situ gel in nasal [J]. Lishizhen Med Mater Med Res (ʱ���ҽ��ҩ),2010,21(9):2296-2298.
[13]
WU J Y,WANG Z Q,HUANG X S,et al. Preparation and quality control of a nasal spray of ofloxacin and ephedrine hydrochloride[J]. Strait Pharm J (��Ͽҩѧ),2008,20(10):21-24.
[14]
SUN J L,CHEN Q X,TIAN S,et al.Absorption of risperidone polymorphs administrated orally in rats[J]. Chin Pharm J (�й�ҩѧ��־),2011,46(24):1919-1922.
[15]
DU G N,GAO Y L,PAN W S. Evaluation of the influencing factors on the ciliotoxicity of nalmefen hydrochloride nasal sprays[J]. Chin J New Drugs(�й���ҩ��־),2007,16(15):1199-1202.
[16]
CHEN J,GAO X L,JIANG X G. Determination of dissolution of resperidone tablets by HPLC[J]. Chin J Mod Appl Pharm (�й��ִ�Ӧ��ҩѧ��־),2006,23(1):62-64.
[17]
PRIYANKA A,SHRINGI S,SANJAY G. Permeability issues in nasal drug delivery[J]. Drug Discovery Today,2002,7(18):967-975.
[18]
WANG Y,WANG Z J. Review on the application of carbomer in pharmceutics[J]. Chin Pharm Aff (�й�ҩ��),2005,19(6):361-365.
[19]
TAS C,OZKAN C K,SAVASER A,et al. Nasal absorption of metoclopramide from different Carbopol 981 based formulations:In vitro,ex vivo and in vivo evaluation[J]. Eur J Pharm Biopharm,2006,64(2):246-254.
2016, Vol. 51 
